Difference between revisions of "GD2-CART01"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | CAR- | + | Anti-GD2 CAR T-cell |
==Preliminary data== | ==Preliminary data== | ||
| Line 6: | Line 6: | ||
#'''GD2CAR01:''' Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. [https://doi.org/10.1056/nejmoa2210859 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37018492/ PubMed] [https://clinicaltrials.gov/study/NCT03373097 Clinical Trial Registry] | #'''GD2CAR01:''' Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. [https://doi.org/10.1056/nejmoa2210859 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37018492/ PubMed] [https://clinicaltrials.gov/study/NCT03373097 Clinical Trial Registry] | ||
| − | [[Category: | + | [[Category:Anti-GD2 CAR T-cells]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Anti-GD2 cellular therapy]] | [[Category:Anti-GD2 cellular therapy]] | ||
| Line 12: | Line 12: | ||
[[Category:Neuroblastoma medications (investigational)]] | [[Category:Neuroblastoma medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
| + | [[Category:Stub]] | ||
Revision as of 15:38, 28 June 2023
Mechanism of action
Anti-GD2 CAR T-cell
Preliminary data
Neuroblastoma
- GD2CAR01: Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. link to original article PubMed Clinical Trial Registry